Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BioCardia, Inc. (BCDA)

BioCardia says FDA accepted Helix catheter De Novo pre-submission package

Neutral Impact 3 of 5 legal/regulatory Written later

BioCardia said the FDA has accepted its revised De Novo pre-submission package for marketing clearance of its Helix catheter, and it expects FDA substantive review and a meeting this quarter. The filing does not report any financial results, and clearance is not yet granted, so the update is a regulatory milestone rather than a change in reported financial performance.

Key points

  • FDA accepted the revised De Novo pre-submission package, announced October 19, 2026
  • Company met with FDA in May 2026 and FDA confirmed and accepted the meeting minutes in August 2026
  • Revised package was re-submitted in September 2026 and BioCardia expects FDA substantive review and a meeting this quarter
  • Company cites clinical data from fifteen clinical trials including nearly five hundred patients

The filing

CompanyBioCardia, Inc. (BCDA)
Form8-K, current report
Filed with the SECOct 19, 2026, 9:15 AM ET
Accession number0001437749-26-032887

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.